OakChart

Agilent Technologies Inc

AHealthcare·Diagnostics & Research·USA·Large·NYSE·Nov 13 • 6:16 AM ET

173.75+0.74 (0.43%)
2026-11-13 12:39 CET
Market cap
$48.98B
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
Price / earnings
34.21
Compare

Price

A against its 20, 50 and 200-day averages
Terms2050200Miss
Patternshover a marker to name it
RS 83120.00140.00160.00180.003.3M6.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26Aclose 173.7520-day 175.5750-day 168.37200-day 137.96173.7552w high 182.9952w low 108.3552-week range, not 6 monthsEarnings in 6 sessions

5.1% under the 52-week high of 182.99 on 28 Oct 2026. 52-week low 108.35 on 20 May 2026. Last 15 sessions, 7.0% high to low

Volume 0.00× normal · the line is the 50-bar volume average

Setup. RS line 83
CANSLIM 3 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Performance: Year +50%
VCP 5 of 6 — fails: Average True Range: Under 2
Minervini 3 of 4 — fails: Performance: Year +50%
Zanger 2 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: Performance: Year +50%
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25
Value 1 of 4 — fails: P/E: Under 15; P/B: Under 2; Debt/Equity: Low (<0.1)
Income 1 of 4 — fails: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: Float: Under 100M; Performance: Year +50%
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Performance: Year +100%

Profile

A
52-week range, 88% of the way up
108.35182.99

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. The Life Sciences and Diagnostics Markets segment offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. The Applied Markets segment refers to the application-focused solutions that include instruments and software that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products. The Agilent CrossLab segment spans the entire lab with its extensive services and consumables portfolio in addition to software and laboratory automation solutions. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

IndexS&P 500, RUI
Employees18100
IPONov 18, 1999
Beta1.24
ATR, 14d4.90
Rel volume0.00
Short float1.74%
Insider own0.32%
Inst own96.43%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap$48.98B
Enterprise Value51.18B
Income1.44B
Sales7.37B
Book / share26.11
Cash / share6.24
Dividend Est.1.02 (0.59%)
Dividend TTM1.02 (0.59%)
Dividend Ex-DateOct 06, 2026
Dividend Gr. 3/5Y5.63% 6.58%
Payout21.70%
Employees18100
IPONov 18, 1999

Ratios

Price / earnings34.21
Forward price / earnings25.93
Price / earnings / growth2.62
Price / sales6.64
Price / book6.65
Price / cash27.86
Price / free cash flow38.66
Value / cash profit25.00
Value / sales6.94
Quick Ratio1.56
Current Ratio2.05
Debt / equity0.54
Long-term debt / equity0.50
Options and shortYes / Yes

Earnings

Earnings / share5.08
Earnings next year6.70
Earnings next quarter1.73
Earnings this year10.94%
Earnings next year8.04%
Earnings growth, 5 years9.88%
Past earnings growth3.03% 14.68%
Past sales growth0.48% 5.41%
Earnings vs last year19.07%
Sales vs last year8.60%
Earnings vs last quarter8.50%
Sales vs last quarter8.06%
EarningsNov 23 AMC
Surprise8.85% 1.98%

Ownership

Insiders own0.32%
Insider trades-0.25%
Institutions own96.43%
Institution trades-0.46%
Return on assets11.00%
Return on equity20.97%
Return on capital13.08%
Gross Margin53.72%
Operating margin24.09%
Profit Margin19.53%
20-day average-1.04%
50-day average3.19%
200-day average25.94%

Technical

Shares out281.97M
Shares floating281.04M
Short / float1.74%
Short ratio2.13
Short interest4.89M
52-week high182.99 -5.1%
52-week low108.35 +60.4%
Volatility2.48% 2.97%
Average range4.90
Strength index50.31
Market sensitivity1.24
Relative volume0.00
Avg Volume2.30M
Volume108

Performance

Perf Week-0.58%
Perf Month-1.03%
Perf Quarter17.04%
Perf Half Y55.55%
Perf YTD27.69%
Perf Year18.28%
Perf 3Y61.69%
Perf 5Y8.00%
Perf 10Y274.70%
Recommendation1.84
Target Price184.11
Prev Close173.01
Price173.75
Change %0.43%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 26, 2026InitiatedDeutsche BankBuy$190+9.4%
Sep 09, 2026ResumedUBSNeutral$165-5.0%
Jul 09, 2026ResumedJefferiesHold$135-22.3%
Jun 26, 2026ResumedBernsteinOutperform$155-10.8%
Jun 11, 2026InitiatedPiper SandlerNeutral$150-13.7%
May 28, 2026UpgradeBofA SecuritiesNeutral → Buy$145-16.5%
May 27, 2026InitiatedRBC Capital MktsOutperform$153-11.9%
Jan 20, 2026InitiatedHSBC SecuritiesBuy$180+3.6%
Jan 05, 2026UpgradeEvercore ISIIn-line → Outperform$160-7.9%
Dec 15, 2025UpgradeBarclaysEqual Weight → Overweight$165-5.0%

Peers

Mkt cap
TickerCompanyMkt cap
WATWaters Corp45.43B
TMOThermo Fisher Scientific Inc260.00B
DHRDanaher Corp163.33B
MTDMettler-Toledo International Inc34.43B
RVTYRevvity Inc17.63B
QGENQiagen NV10.34B
BRKRBruker Corp9.21B
ILMNIllumina Inc31.53B
BIOBio-Rad Laboratories Inc10.00B
AVTRAvantor Inc10.64B

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Dolsten MikaelDirectorSep 04 '26Sale151.3863495,9724,924Sep 09 04:01 PM
Dolsten MikaelDirectorSep 04 '26Proposed Sale151.3863495,972Sep 04 04:19 PM
Dolsten MikaelDirectorMay 29 '26Sale135.421,600216,6725,548Jun 02 04:01 PM
Dolsten MikaelDirectorMay 29 '26Proposed Sale135.421,600216,672May 29 04:45 PM
Dolsten MikaelDirectorDec 01 '25Sale149.812,600389,5114,973Dec 03 04:04 PM
Gonsalves RodneyV.P., Corporate ControllerNov 26 '25Sale154.993,000464,95631,846Dec 01 04:29 PM
Dolsten MikaelDirectorDec 01 '25Proposed Sale149.812,600389,510Dec 01 04:26 PM
Gonsalves RodneyOfficerNov 26 '25Proposed Sale154.993,000464,956Nov 26 02:26 PM
MCDONNELL PADRAIGPresident and CEONov 18 '25Sale143.24911130,49232,058Nov 20 05:22 PM
MCDONNELL PADRAIGOfficerNov 18 '25Proposed Sale143.24911130,492Nov 18 10:37 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VOOVanguard S&P 500 ETFAUM: 1070.75B
VOVanguard Morningstar Mid-Cap ETFAUM: 108.45B
IVViShares Core S&P 500 ETFAUM: 882.14B
SPYSPDR S&P 500 ETF TrustAUM: 805.69B
VTVVanguard Morningstar Value ETFAUM: 198.14B
VOTVanguard Morningstar Mid-Cap Growth ETFAUM: 19.06B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.51B
VIGVanguard Dividend Appreciation FTFAUM: 117.98B
RSPInvesco S&P 500 Equal Weight ETFAUM: 105.70B

News

latest 14 of 200

Quarterly earnings

actual against estimate

No quarterly earnings.

Annual earnings

No annual earnings.

Quarterly results

2026Q3 revenue 1,878, from 1,738 a year earlier. Operating margin 26.7%, from 22.2% a year earlier
Revenue, USD millions
1,87802024Q4 revenue 1,70124Q42025Q1 revenue 1,68125Q12025Q2 revenue 1,66825Q22025Q3 revenue 1,73825Q32025Q4 revenue 1,86125Q42026Q1 revenue 1,79826Q12026Q2 revenue 1,83526Q22026Q3 revenue 1,87826Q3
Operating margin
26.702024Q4 operating margin 25.2%24Q42025Q1 operating margin 23.1%25Q12025Q2 operating margin 21.2%25Q22025Q3 operating margin 22.2%25Q32025Q4 operating margin 23.8%25Q42026Q1 operating margin 20.9%26Q12026Q2 operating margin 24.9%26Q22026Q3 operating margin 26.7%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type.

No estimate revisions.

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share2.10.9723.3682.3053.9414.184.1894.434.5725.0791-
Sales USD millions4,4724,9145,1635,3396,3196,8486,8336,5106,9487,372-
Shares million shares322318309306302295292285283-282
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share0.9691.2231.1080.7541.1791.5281.0741.1981.279
Sales USD millions1,5781,7011,6811,6681,7381,8611,7981,8351,878
Shares million shares288285285284284283283282282

Income statement, annual

No statement data.

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q37/31/20262026Q24/30/20262026Q11/31/20262025Q410/31/20252025Q37/31/20252025Q24/30/20252025Q11/31/20252024Q410/31/2024
Total Revenue1,878.00+8.1%1,835.00+10.0%1,798.00+7.0%1,861.00+9.4%1,738.00+10.1%1,668.00+6.0%1,681.00+1.4%1,701.00+0.8%
Cost of Goods Sold Incl. D&A836.00-0.2%844.00+6.6%848.00+7.9%884.00+13.9%838.00+18.0%792.00+10.5%786.00+5.5%776.00+1.8%
Gross Profit1,042.00+15.8%991.00+13.1%950.00+6.1%977.00+5.6%900.00+3.7%876.00+2.3%895.00-2.0%925.00-0.1%
Selling, General and Administrative Excl. Other540.00+4.9%535.00+2.5%575.00+13.4%534.00+7.4%515.00+11.2%522.00+5.9%507.00-1.2%497.00-1.2%
Research and Development120.00+8.1%126.00+15.6%117.00+9.3%117.00+6.4%111.00+1.8%109.00-3.5%107.00-10.8%110.00-3.5%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income502.00+30.4%456.00+28.8%375.00-3.4%443.00+3.5%385.00-4.9%354.00-2.5%388.00-3.0%428.00+1.2%
Interest Expense29.00+3.6%25.00-13.8%24.00-14.3%27.00-15.6%28.00+27.3%29.00+45.0%28.00+27.3%32.00+52.4%
Unusual Expense62.00+226.3%61.00-17.6%18.00+12.5%11.00-21.4%19.00-71.2%74.0016.00+33.3%14.00-73.1%
Net Income Before Taxes444.00+21.3%408.00+56.9%364.00-0.8%442.00+10.2%366.00+6.7%260.00-30.5%367.00-8.9%401.00-4.5%
Income Taxes82.00+173.3%69.00+53.3%59.00+20.4%8.00-84.0%30.00-50.8%45.00-31.8%49.00-10.9%50.00
Consolidated Net Income362.00+7.7%339.00+57.7%305.00-4.1%434.00+23.6%336.00+19.1%215.00-30.2%318.00-8.6%351.00-26.1%
Net Income From Continuing Operations362.00+7.7%339.00+57.7%305.00-4.1%434.00+23.6%336.00+19.1%215.00-30.2%318.00-8.6%351.00-26.1%
Net Income362.00+7.7%339.00+57.7%305.00-4.1%434.00+23.6%336.00+19.1%215.00-30.2%318.00-8.6%351.00-26.1%
EPS (Recurring) per share1.43+16.3%1.35+43.6%1.12-2.6%1.56+23.8%1.23+8.8%0.94-9.6%1.15-5.0%1.26-28.0%
EPS (Basic, Before Extraordinaries) per share1.28+8.5%1.20+60.0%1.08-3.6%1.53+24.4%1.18+21.6%0.75-28.6%1.12-5.9%1.23-24.5%
EPS (Diluted) per share1.28+8.5%1.20+60.0%1.07-3.6%1.53+25.4%1.18+21.6%0.75-28.6%1.11-5.9%1.22-24.7%
EBITDA568.00+24.3%523.00+22.5%442.00-3.9%514.00+3.4%457.00-2.4%427.00+0.2%460.00-0.4%497.00+2.5%
Non-Operating Income (Expense)33.00+17.9%38.00+322.2%31.00+34.8%37.00+94.7%28.00+7.7%9.00-64.0%23.00-37.8%19.00-72.9%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense24.49-3.1%26.86+13.3%32.390.0%20.54-21.0%25.28-9.7%23.70-25.9%32.39-6.8%26.00+135.1%
Price To Earnings Ratio ratio statement ratio, not the snapshot34.0625.4829.2934.3228.3224.7334.2327.01
Price To Sales Ratio ratio5.314.525.385.984.824.636.665.74
Gross Margin %55.4854.0152.8452.5051.7852.5253.2454.38
Operating Margin %26.7324.8520.8623.8022.1521.2223.0825.16
Net Margin %19.2818.4716.9623.3219.3312.8918.9220.63
Shares Outstanding million shares281.97-0.6%282.22-0.6%282.70-0.9%283.05-0.8%283.59-1.4%283.94-2.6%285.23-2.7%285.19-2.4%
Market Capitalization48,776.54+49.6%32,654.66+6.4%37,858.13-12.5%41,493.06+10.8%32,613.50-20.9%30,677.08-23.6%43,273.35+13.5%37,441.71+23.8%

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

The feed stopped.

No statement data.

Cash flow, quarterly

The feed stopped.

No statement data.

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Product4,672.004,944.00+5.8%71.2%
Service, Other1,838.002,004.00+9.0%28.8%
Total6,510.006,948.00+6.7%100.0%
Region
Name20242025vs 20242025 share
Americas2,573.002,806.00+9.1%40.4%
Asia Pacific2,167.002,219.00+2.4%31.9%
Europe1,770.001,923.00+8.6%27.7%
Total6,510.006,948.00+6.7%100.0%
Segment
Name20242025vs 20242025 share
Agilent CrossLab2,747.002,908.00+5.9%41.9%
Applied Markets1,297.001,314.00+1.3%18.9%
Life Sciences and Diagnostics Markets2,466.002,726.00+10.5%39.2%
Total6,510.006,948.00+6.7%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.74%4.9M281.0M2.22M
2026-10-151.79%5.0M281.0M2.25M
2026-09-301.87%5.2M281.0M2.27M
2026-09-151.81%5.1M281.0M2.19M
2026-08-312.02%5.7M281.0M2.23M
2026-08-141.84%5.2M281.5M2.28M
2026-07-312.04%5.7M281.5M2.41M
2026-07-152.68%7.5M281.5M2.36M
2026-06-301.89%5.3M281.5M2.27M
2026-06-152.01%5.7M281.3M2.22M
2026-05-291.85%5.2M281.5M2.27M
2026-05-151.95%5.5M281.7M2.23M
2026-04-301.71%4.8M281.8M2.23M
2026-04-151.59%4.5M281.8M2.22M
2026-03-311.61%4.5M281.8M2.30M
2026-03-131.70%4.8M281.8M2.25M
2026-02-271.62%4.6M281.8M2.16M
2026-02-131.52%4.3M282.1M2.07M
2026-01-301.52%4.3M281.5M1.99M
2026-01-151.41%4.0M282.1M1.92M

Option chain

expiry -
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

0
FiledFormDescriptionPeriodLink
No filings.

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090095.97K1
2026-080000
2026-070000
2026-060000
2026-0500216.67K1
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200389.51K1
2025-11002.47M3

Institutional holders

Manager% owned
BlackRock, Inc.9.06%
VANGUARD CAPITAL MANAGEMENT LLC6.53%
VANGUARD PORTFOLIO MANAGEMENT LLC5.11%
STATE STREET CORP4.60%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.24%
T. Rowe Price Investment Management, Inc.2.75%
GEODE CAPITAL MANAGEMENT, LLC2.72%
WELLINGTON MANAGEMENT GROUP LLP2.64%
Bank of New York Mellon Corp2.50%
FMR LLC2.43%

Funds

Fund% owned
VANGUARD INTERMEDIATE-TERM INVESTMENT-GRADE FUND12.07%
First Trust Enhanced Short Maturity ETF8.85%
VANGUARD SHORT-TERM INVESTMENT-GRADE FUND8.32%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND7.94%
PGIM Ultra Short Bond ETF7.36%
Invesco Ultra Short Duration ETF7.08%
VANGUARD INSTITUTIONAL INTERMEDIATE-TERM BOND FUND5.21%
Baird Aggregate Bond Fund4.96%
T. Rowe Price Short-Term Bond Fund, Inc.4.83%
Invesco Conservative Income Fund3.54%

OakChart. A. Cached 15 minutes. Terms

Some panels did not load: ea, fc, oc, lf.